ACM
PBYI icon

Acrisure Capital Management’s Puma Biotechnology PBYI Stock Holding History

Acrisure Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,409
Closed -$107K – 354
2022
Q4 		$107K Buy
+25,409
New +$87.7K 0.12% 230

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Acrisure Capital Management's PBYI Position: Q1 2023 in Review

Acrisure Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 25,409 shares — an estimated $107K sold.

Acrisure Capital Management first reported a position in PBYI in Q4 2022 and held it in 1 quarter. The position peaked at $107K in Q4 2022. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • Acrisure Capital Management reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 25,409 Puma Biotechnology shares in Q1 2023, an estimated $107K.
  • Acrisure Capital Management first reported a position in Puma Biotechnology in Q4 2022 and held it in 1 quarter.
  • Acrisure Capital Management's Puma Biotechnology position peaked at $107K in Q4 2022.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on Acrisure Capital Management's 13F filing for Q1 2023, filed 15 May 2023.